Will CAR T cells give new therapies for NHL and CLL a run for their money?
During the recent American Society of Hematology meeting, much of the focus in immuno-oncology was squarely on the pediatric and adult data using the chimerica antigen receptor T cell product being developed by Novartis, CTL019, in acute lymphoblastic leukemia (ALL) from Children’s Hospital of Philadelphia (CHOP, not to be confused with the chemotherapy regimen!) and U Penn, respectively. We wrote about that data earlier this year.
There are, hovever, other interesting CAR T cell therapies in clinical development, including those from Juno (based on the MSK and Fred Hutchinson partnership), Bluebird in partnership with Celgene and one that actually had data at ASH, which didn’t receive much attention from the NCI and Kite Pharma. This therapy was evaluated in a trial of non Hodgkin’s Lymphoma (NHL) patients.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
